Bronchiectasis: An update on current pharmacotherapy and future perspectives

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 4, 2014, Pages 505-525

  Sidhu, Manjit K ^a,b   Mandal, Pallavi ^b   Hill, Adam T ^a,b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Bronchiectasis; Exacerbations; Pharmacotherapy; Stable state

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; BECLOMETASONE; BRONCHODILATING AGENT; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERYTHROMYCIN; FLUTICASONE; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; IPRATROPIUM BROMIDE; LACTULOSE; LEVOFLOXACIN; MACROLIDE; MANNITOL; OLEANDOMYCIN PLUS TETRACYCLINE; PENICILLIN DERIVATIVE; PLACEBO; SODIUM CHLORIDE; TERBUTALINE; TETRACYCLINE; TOBRAMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; BREATHING EXERCISE; BRONCHIECTASIS; CHEST INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; HUMAN; MEDLINE; MICROBIOLOGY; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; RESPIRATORY FUNCTION; REVIEW; SPUTUM VISCOSITY; ST. GEORGE RESPIRATORY QUESTIONNAIRE;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHIECTASIS; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MUCOCILIARY CLEARANCE; RESPIRATORY TRACT INFECTIONS;

EID: 84893685500     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.878330     Document Type: Review

References (64)

1. Wilson R. Bronchiectasis. In: Gibson GJ, et al. editors, Respiratory medicine. Volume 2. 3rd edition. Elsevier Science Ltd, London; 2003
2. Management of bronchiectasis. Drug Ther Bull 2003;41(12):91-5
3. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis Non-CF Guideline Group. British thoracic society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):1-58
4. Cole P, Wilson R. Host-microbial interrelationships in respiratory infection. Chest 1989;95:217S-21S
5. Angrill J, Agust? C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002;57(1):15-19
6. Chalmers JD, Smith MP, McHugh BJ, et al. Short-And long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186(7):657-65
7. Hill SL, Morrison HM, Burnett D, Stockley RA. Short term response of patients with bronchiectasis to treatment with amoxicillin given in standard or high doses orally or by inhalation. Thorax 1986;41:559-65
8. Chan TH, Ho SS, Lai CK, et al. Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. Chemotherapy 1996;42:150-6
9. Lam WK, Chau PY, So SY, et al. Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis. Respir Med 1989;83:299-303
10. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130(5):1503-10
11. Tsang KW, Chan WM, Ho PL, et al. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. Eur Respir J 1999;14:1206-9
12. Brambilla C, Kastanakis S, Knight S, Cunningham K. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1992;11(2):118-24
13. Mehta AP, Phutane L, Patel MH, et al. Comparative study of amoxycillin and amoxycillin/clavulanic acid in lower respiratory infections. J Assoc Physicians India 1991;39(3):251-3
14. Abu Hassan J, Saadiah S, Roslan H, Zainudin BM. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology 1999;4:423-6
15. Franco F, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev 2003;(3):CD003572
16. Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev 2001;(2):CD002163
17. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005;99(1):27-31
18. Kellett F, Niven RM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105:1831-5
19. Nicolson C, Stirling R, Borg B, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106:661-7
20. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006;(2):CD002996
21. Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159:1843-8
22. Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005;10:46-56
23. Daviskas E, Anderson SD, Eberl S, Young I. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008;31:765-72
24. Daviskas E, Anderson SD, Gomes K, et al. Increase in health status after 12 days treatment with inhaled mannitol in patients with bronchiectasis. Eur Respir J 2003;22(Suppl 45):430
25. Bilton D, Daviskas E, Anderson S, et al. A phase III randomised study of the efficacy and safety of inhaled dry powder mannitol (Bronchitol) for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25
26. Crockett A, Cranston JM, Alpers JH, Latiner KM. Mucolytics for bronchiectasis (Review). Cochrane Database Syst Rev 2001;(1):CD001289
27. Olivieri D, Ciaccia A, Marangio E, et al. Role of bromhexine in exacerbations of bronchiectasis. Respiration 1991;58:117-21
28. Wills PJ, Wodehouse T, Corkery K, Mallon K. Short-term recombinant human DNase in bronchiectasis. Am J Respir Crit Care Med 1996;154:413-17
29. ODonnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase 1. Chest 1998;113:1329-34
30. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis (Review). Cochrane Database Syst Rev 2009;(1):CD000996
31. Tsang KW, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998;158:723-7
32. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005;60:239-43
33. Elborn JS, Johnston B, Allen F, et al. Inhaled steroids in patients with bronchiectasis. Respir Med 1992;86(2):121-4
34. Mart?nez-Garcia M, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna J. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006;100:1623-32
35. Martinez-Garcia M, Soler-Cataluna J, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141:461-8
36. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306
37. Pizzutto S, Upham J, Yerkovich S, Chang A. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2010;(4):CD007525
38. Tamaoki J, Chiyotani A, Kobayashi K, et al. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 1992;145(3):548-52
39. Llewellyn-Jones CG, Johnson M, Mitchell JL, et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995;8(9):1479-87
40. Vandermeer M, Thomas A, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratoryconfirmed influenza virus infections: a multistate study. J Infect Dis 2012;205:13-32
41. Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med 2013;107:524-33
42. Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council. BMJ 1957;2:255-9
43. Sobel S, Lichter EA, Davis JC, et al. Adverse reactions to tetracycline, penicillin and an oleandomycin-penicillin mixture used in the long-term therapy of chronic pulmonary disease. Am J Med Sci 1962;243:341-53
44. Cherniack N, Vosti K, Dowling H, et al. Long-term treatment of bronchiectasis and chronic bronchitis; a controlled study of the effects of tetracycline, penicillin, and an oleandomycinpenicillin mixture. AMA Arch Intern Med 1959;103(3):345-53
45. Dowling H, Mellody M, Lepper M, Jackson G. Bacteriologic studies of the sputum in patients with chronic bronchitis and bronchiectasis. Results of continuous therapy with tetracycline, penicillin, or an oleandomycin-penicillin mixture. Am Rev Respir Dis 1960;81:329-39
46. Currie DC, Garbett ND, Chan KL, et al. Double-blind randomised study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990;76:799-816
47. Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999;13:361-4
48. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380(9842):660-7
49. Altenburg J, De Graaff C, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. The bat randomized controlled trial. JAMA 2013;309(12):1251-9
50. Serisier D, Martin M, McGuckin M, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with noncystic fibrosis bronchiectasis. The bless randomized controlled trial. JAMA 2013;309(12):1260-7
51. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. NEJM 2012;366(20):1881-90
52. Lin HC, Cheng HF, Wang CH, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997;155:2024-9
53. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481-5
54. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41:1107-15
55. Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44
56. Serisier D, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68:812-17
57. Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93:476-80
58. Murray MP, Govan J, Doherty C, et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183:491-49
59. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstrutive pulmonary disease. Am J Respir Crit Care Med 2013;188(10):1224-31
60. Hill AT, Bilton D, Brown J, et al. British thoracic society quality standards for clinically significant bronchiectasis in adults July 2012. Br Thorac Soc Rep 2012;4:1-16
61. Adjemian J, Olivier K, Seitz A, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185(8):881-6
62. Olivier K, Weber D, Lee J, et al. Non-tuberculous mycobacterium. Am J Respir Crit Care Med 2003;167(6):828-34
63. Schembri S, Williamson P, Short P, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013;346:1235-46
64. Mandal P, Sidhu M, Donaldson L, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013;106(1):27-33